Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENSBiotechnology
-$0.02 today
- Market cap
- $141.41M
- Beta
- 2.08
- P/E (TTM)
- -25.1
- EPS (TTM)
- -$0.06
Volume 0.07M
Average 0.10M
MENS Total Non-current Liabilities
All obligations due after more than one year.
Jyong Biotech Ltd. Ordinary SharesNASDAQ: MENS
Total Non-current Liabilities · Q4 FY2025 · quarter ended Dec 2025
Total non-current liabilities falls 64.6% from a year ago
Total non-current liabilities stood at $10.87M at the end of Q4 FY2025, down 64.6% from a year earlier. Over 3 fiscal years it compounded at -24.7% a year.
Context
- Total non-current liabilities amounted to 52.3% of total assets at the end of Q4 FY2025, down 430.8 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -64.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 10.87M USD
- Year-over-year change
- -64.6%
- 4-year CAGR
- -19.9%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.87M | -64.6% |
| FY2024 | 2024-12-31 | 30.76M | +9.6% |
| FY2023 | 2023-12-31 | 28.06M | +10.2% |
| FY2022 | 2022-12-31 | 25.47M | -3.8% |
| FY2021 | 2021-12-31 | 26.46M | — |
Total Non-current Liabilities vs competitors
How MENS compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -64.6% is the lowest of 11, against a peer median of +19.2%.
- Total non-current liabilities amounts to 52.3% of total assets for MENS, versus a peer median of 19.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.2B USD | +38.1% | +9.4% | 92.6% | |
AAPGAscentage Pharma Group International | Dec 2025 | CN¥986.62M CNY | -16.2% | -13.8% | 24.9% |
| Jun 2026 | $754.13M USD | +659.6% | +109.4% | 91.1% | |
| Sep 2026 | $614.73M USD | +86.3% | -12.2% | 72.5% | |
| Jun 2026 | $213.83M USD | +84.2% | +85.1% | 21.5% | |
| Sep 2026 | $119.1M USD | -55.6% | -30.9% | 7.1% | |
| Mar 2026 | $117.84M USD | +0.4% | +19.0% | 18.4% | |
| Jun 2026 | $103.7M USD | +1420.5% | — | 7.8% | |
| Dec 2025 | $10.87M USD | -64.6% | -24.7% | 52.3% | |
| Sep 2026 | $9.27M USD | -21.0% | +4.5% | 0.9% | |
| Sep 2026 | $8.19M USD | -18.0% | +230.2% | 0.7% | |
| Peer median (excluding MENS) | — | +19.2% | +9.4% | 19.9% | |
Competitors are the stored peer set for MENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 551K | 718K | 177K | 98K | 1.18M |
| Short-term Investments | 1.83M | 94K | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 13.51M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 263K | 1.65M | 1.66M | 108K | 854K |
| Total Current Assets | 2.65M | 2.46M | 1.84M | 206K | 15.54M |
| Property, Plant & Equipment (Net) | 6.78M | 6M | 3.54M | 3.19M | 5.23M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 8K | 283K | 2.87M | 2.97M | 6K |
| Total Non-current Assets | 6.78M | 6.28M | 6.41M | 6.16M | 5.24M |
| Total Assets | 9.43M | 8.75M | 8.25M | 6.37M | 20.78M |
| Account Payables | 46K | 4K | 2K | 3K | 2K |
| Short-term Debt | 4.93M | 7.65M | 7.97M | 7.28M | 8.36M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 23K | 4.22M | 4.99M | 3.33M | 26.31M |
| Total Current Liabilities | 6.29M | 12.91M | 14.26M | 12.13M | 34.81M |
| Long-term Debt | 6.26M | 6.32M | 8.52M | 10.68M | 10.16M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 19.86M | 19.04M | 19.47M | 20.06M | 688K |
| Total Non-current Liabilities | 26.46M | 25.47M | 28.06M | 30.76M | 10.87M |
| Total Liabilities | 32.76M | 38.38M | 42.32M | 42.89M | 45.68M |
| Common Stock | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | (19.03M) | (25.66M) | (30.06M) | (33.08M) | (37.75M) |
| Accumulated OCI | 266K | 590K | 548K | 1.12M | 682K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (23.33M) | (29.63M) | (34.07M) | (36.52M) | (24.91M) |
| Total Debt | 11.79M | 14.25M | 16.69M | 18.14M | 18.55M |
| Net Debt | 11.24M | 13.53M | 16.51M | 18.04M | 17.37M |
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
Intrinsic Alpha fair value
Locked
Current Price
$1.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.